Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is orally active and acts... Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.
- Mechanism
- Curator reviewed
Cilomilast shows high selectivity for cAMP-specific PDE4, an isoenzyme that predominates in pro-inflammatory and immune cells and that is 10-fold more selective for PDE4D than for PDE4A, -B or -C. In vitro, cilomilast suppresses the activity of several pro-inflammatory and immune cells that have been implicated in the pathogenesis of asthma and COPD. Moreover, it is highly active in animal models of these diseases. Cilomilast has been shown to exert potent anti-inflammatory effects both in vitro and in vivo.
- Primary indication
- Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).Curator reviewed
- Formula / weight
- C20H25NO4 · 343.4168 g/mol (avg)
- Also known as
- Ariflo
- Code names
- SB-207,499
Resolves to
CFBUZOUXXHZCFB-OYOVHJISSA-NSMILESCOC1=C(OC2CCCC2)C=C(C=C1)[C@]1(CC[C@@H](CC1)C(O)=O)C#NWhat you can answer from here — as of August 30, 2026
Which drugs share a target with Cilomilast, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account